Search

Your search keyword '"niraparib"' showing total 213 results
Start Over Descriptor "niraparib" Database Gale General OneFile
213 results on '"niraparib"'

1. Gynecologic cancer

Author

Zhou, Zhen Ni and Wright, Jason D.

Subjects
Mortality, Rucaparib, Niraparib, Cancer -- Care and treatment -- Development and progression, Olaparib, Bevacizumab, Endometrial cancer -- Care and treatment -- Development and progression, Recurrence (Disease) -- Care and treatment -- Development and progression, Carboplatin, Radiotherapy, Adjuvant chemotherapy, Ovarian cancer -- Care and treatment -- Development and progression, Chemotherapy, Cancer treatment, Surgery, Clinical trials, Health
Abstract

Gynecologic malignancies continue to be a major cause of cancer-related mortality. In this article: adjuvant chemotherapy during and after radiation for high-risk endometrial cancers; PARP inhibitors with first-line chemotherapy and [...]

Published
2020

2. What Medical-Surgical Nurses Need to Know About Caring for Patients with Epithelial Ovarian Cancer: Part II

Author

Bohnenkamp, Susan, McClung, Emily, and Bohnenkamp, Zachary

Subjects
Surgical nursing, Evidence-based medicine, Olaparib, Bevacizumab, Chemotherapy, Carboplatin, Epidemiology, Nurses, Cancer patients -- Care and treatment, Antineoplastic agents, Ovarian cancer -- Prevention -- Care and treatment -- Risk factors, Hospital patients, Cancer treatment, Niraparib, Hormones, Pazopanib, Nursing, Nursing care, Rucaparib, Health, National Comprehensive Cancer Network
Abstract

Ovarian cancer is a very complex disease with varied local and systemic treatments. Treatment options, including surgery, chemotherapy, hormone therapy, and targeted therapy, as well as prevention of complications after [...]

Published
2019

3. Gynecologic cancer

Author

Gamble, Charlotte and Wright, Jason D.

Subjects
Cancer -- Care and treatment, Niraparib, Adjuvant chemotherapy, Olaparib, Women's health, Hysterectomy, Carboplatin, Ovarian cancer -- Care and treatment, Rucaparib, Bevacizumab, Chemotherapy, Cancer treatment, Cancer patients, Monosaccharides, Clinical trials, Health
Abstract

Gynecologic malignancies continue to be among the most deadly cancers for women. In this article: HIPEC, PARP, and minimally invasive hysterectomy Of the major developments in 2018 that changed practice [...]

Published
2019

4. Olaparib, a new hope for ovarian cancer

Author

Samoon, Zarka and Jabbar, Adnan

Subjects
Niraparib, Olaparib, Bevacizumab, Ovarian cancer -- Genetic aspects, Pazopanib, Health
Abstract

Byline: Zarka. Samoon, Adnan. Jabbar Ovarian cancer is the most common cause of death among gynecologic cancers and has a cure rate of less than 40% in women.[1] Around 70% [...]

Published
2020

5. EC approves GSK's Zejula as first-line monotherapy maintenance treatment in advanced ovarian cancer

Subjects
Niraparib, Chemotherapy, Drug approval, Ovarian cancer -- Drug therapy, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission, Zejula (Medication)
Abstract

GlaxoSmithKline (GSK) announced the European Commission (EC) has approved Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as first-line monotherapy maintenance treatment for adult patients with advanced epithelial [...]

Published
2020

6. EMA committee recommends approval of GSK's Zejula as first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer

Subjects
Niraparib, Chemotherapy, Ovarian cancer -- Care and treatment, Pharmaceuticals and cosmetics industries, Zejula (Medication)
Abstract

GlaxoSmithKline (GSK) plc announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Zejula (niraparib), an oral poly [...]

Published
2020

7. Zai Lab announced results from NORA study

Subjects
Zai Lab Ltd., Niraparib, Pharmaceutical industry, Business, News, opinion and commentary, Zejula (Medication)
Abstract

Zai Lab has announced detailed positive results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled study of ZEJULA as a maintenance therapy in Chinese patients with recurrent epithelial [...]

Published
2020

8. Investigators at University Hospital Erlangen Release New Data on Melanoma (PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts)

Subjects
Physical fitness, Niraparib, Talazoparib, Ionizing radiation, Melanoma, Drug approval, Health
Abstract

2020 SEP 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Melanoma have been published. According to [...]

Published
2020

9. Findings in Neuroblastomas Reported from Institute of Cancer Research (MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma)

Subjects
Genetic research, Physical fitness, Niraparib, Olaparib, Cancer research, Cell death, Neuroblastoma, Health
Abstract

2020 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Neuroblastomas have been published. According to [...]

Published
2020

10. Investigators at Copenhagen University Hospital Target Ovarian Cancer (The forefront of ovarian cancer therapy: update on PARP inhibitors)

Subjects
Cancer treatment, Niraparib, Olaparib, Women's health, Bevacizumab, Medical research, Ovarian cancer -- Drug therapy, Health, Women's issues/gender studies
Abstract

2020 JUL 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Oncology - Ovarian Cancer are discussed in a new report. According [...]

Published
2020

11. US FDA approves Myriad,COs BRACAnalysis CDx test as companion diagnostic for Lynparza to treat metastatic castration-resistant prostate cancer

Subjects
United States. Food and Drug Administration, Myriad Genetics Inc., AstraZeneca PLC, Olaparib, Biotechnology industries, Prostate cancer -- Drug therapy, Pharmaceutical industry, EDTA, Antineoplastic agents, Genes, Medical personnel, Niraparib, Abiraterone, Biotechnology, DNA repair, Precision medicine, Enzalutamide, Novels, Pharmaceuticals and cosmetics industries, Lynparza (Medication)
Abstract

Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that the US Food and Drug Administration (FDA) approved the BRACAnalysis CDx test for use as a companion diagnostic [...]

Published
2020

12. GSK's Zejula gets US FDA approval to treat women with platinum-responsive advanced ovarian cancer

Subjects
United States. Food and Drug Administration, GlaxoSmithKline PLC, Niraparib, Chemotherapy, Pharmaceutical industry, Women, Drug approval, Ovarian cancer -- Genetic aspects, Medical schools, Cancer treatment, Setting (Literature), Monosaccharides, Pharmaceuticals and cosmetics industries, Zejula (Medication)
Abstract

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) approved the companyÇÖs supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as [...]

Published
2020

13. EMA accepts GSK's MAA for Zejula in first-line maintenance treatment for women with platinum-responsive advanced ovarian

Subjects
GlaxoSmithKline PLC, Niraparib, Chemotherapy, Pharmaceutical industry, Ovarian cancer -- Care and treatment, Cancer treatment, Setting (Literature), Pharmaceuticals and cosmetics industries, Zejula (Medication)
Abstract

GlaxoSmithKline plc announced that the European Medicines Agency (EMA) has validated the company's Type II Variation (T2V) for Zejula (niraparib) as a maintenance treatment in the first-line setting for women [...]

Published
2020

14. US FDA accepts GSK's sNDA for Zejula for first-line maintenance treatment for women with platinum-responsive advanced ov

Subjects
United States. Food and Drug Administration, GlaxoSmithKline PLC, Niraparib, Bevacizumab, Chemotherapy, Pembrolizumab, Pharmaceutical industry, Women, Drug approval, Ovarian cancer -- Care and treatment, Time, Cancer treatment, Setting (Literature), Cancer, Pharmaceuticals and cosmetics industries, Zejula (Medication)
Abstract

GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) accepted the company's submission of a supplemental New Drug Application (sNDA) seeking approval of Zejula (niraparib) as a maintenance [...]

Published
2020

15. Researchers Submit Patent Application, 'Diagnosis And Treatment Of Lymphoproliferative Disorders With Parp Inhibitors', for Approval (USPTO 20200022979)

Subjects
Physical fitness, B cells, Olaparib, Antineoplastic agents -- Intellectual property, Acute lymphocytic leukemia, T cells, Obesity, Niraparib, Vincristine, Talazoparib, Editors, Rucaparib, Health
Abstract

2020 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2020

16. Zai Lab Ltd at JPMorgan Healthcare Conference - Final

Subjects
JPMorgan Chase & Co., Zai Lab Ltd., Niraparib, Health care industry, Banking industry, Pharmaceutical industry, Chairpersons, Biotechnology, Health care industry, Banking industry, Business, Zejula (Medication)
Abstract

Presentation ANUPAM RAMA, VP AND ANALYST, JP MORGAN CHASE & CO, RESEARCH DIVISION: We'll go ahead and get started. Yes, so we're getting started with this presentation. Welcome, everybody, to [...]

Published
2020

17. New Findings from University of Texas M.D. Anderson Cancer Center Update Understanding of Xenografts [Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors Induce Autophagy-mediated Drug Resistance In Ovarian Cancer Cells, Xenografts, and ...]

Subjects
United States. National Cancer Institute, Rucaparib, Monosaccharides, ATPases, Niraparib, Olaparib, Women's health, Cancer prevention, Cancer cells, Drug resistance, Adenosine, Ovarian cancer, Cancer research, Talazoparib, Women, Editors, Health, Women's issues/gender studies, University of Texas. M.D. Anderson Cancer Center
Abstract

2019 DEC 5 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Biotechnology - Xenografts is the subject of a report. According to [...]

Published
2019

18. FDA approves niraparib for HRD-positive advanced ovarian cancer

Subjects
United States. Food and Drug Administration, Niraparib, Ovarian cancer, Chemotherapy, Cancer treatment, Marketing, Tumors, Business, News, opinion and commentary
Abstract

On October 23, the Food and Drug Administration approved niraparib, or ZEJULA, marketed by GlaxoSmithKline's (GSK) Tesaro, for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with [...]

Published
2019

19. Ovarian cancer: more women benefit from maintenance combined targeted therapy

Subjects
Niraparib, Olaparib, Bevacizumab, Women's health, Women, Ovarian cancer, Editors, Cancer patients, Health, Women's issues/gender studies
Abstract

2019 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Barcelona, Spain, 28 September 2019 - New data presented at the ESMO Congress 2019 [...]

Published
2019

20. US FDA grants breakthrough therapy status to Janssen's niraparib to treat metastatic castration-resistant prostate cance

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Niraparib, Chemotherapy, Prostate cancer, Pharmaceutical industry, Cancer metastasis, Genes, Cancer treatment, Androgens, Monosaccharides, Pharmaceuticals and cosmetics industries
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) [...]

Published
2019

21. Janssen announces FDA Breakthrough Therapy Designation for niraparib

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Niraparib, Prostate cancer, Pharmaceutical industry, Genes, Chemotherapy, Cancer treatment, Monosaccharides, Cancer metastasis, Business, News, opinion and commentary
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase inhibitor, for [...]

Published
2019

22. GlaxoSmithKline announces results from PRIMA

Subjects
Niraparib, Cancer research, Ovarian cancer -- Development and progression, Death, Women, Company earnings/profit, Business, News, opinion and commentary, Zejula (Medication)
Abstract

GlaxoSmithKline announced results from PRIMA, the Phase 3 randomised, double-blind, placebo-controlled study of Zejula as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. [...]

Published
2019

23. With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis

Subjects
Rucaparib, Physical fitness, Niraparib, Olaparib, Drug approval, DNA, Obesity, Drugs, DNA repair, Editors, Novels, Company investment, Health
Abstract

2019 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Roots Analysis has announced the addition of ' Synthetic Lethality-based Drugs and [...]

Published
2019

24. Zai Lab announces publication of pharmacokinetic study of niraparib

Subjects
Zai Lab Ltd., Niraparib, Medical research, Pharmaceutical industry, Ovarian cancer, Medical supplies, Cancer patients, Business, News, opinion and commentary
Abstract

Zai Lab (ZLAB) announced publication of the open-label study evaluating the pharmacokinetic profile of niraparib in Chinese ovarian cancer patients. Results from the study show a PK profile of niraparib [...]

Published
2019

25. Data from Department of Hematology Provide New Insights into Personalized Medicine (Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies)

Subjects
United States. Food and Drug Administration, Campanulaceae, Cancer, Pembrolizumab, Niraparib, Cervical cancer, Drug approval, Precision medicine, Rucaparib, Olaparib, Bevacizumab, Chemotherapy, Women's health, Clinical trials, Editors, Drugs, Health, Women's issues/gender studies
Abstract

2019 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Drugs and Therapies - Personalized Medicine have been presented. According to [...]

Published
2019

26. New Findings from Duke University Update Understanding of Ovarian Cancer (Targeted Composite Value-based Endpoints In Platinum-sensitive Recurrent Ovarian Cancer)

Subjects
Cancer treatment, Niraparib, Drug approval, Ovarian cancer -- Care and treatment, Recurrence (Disease) -- Care and treatment, Rucaparib, Journalistic ethics, Bevacizumab, Olaparib, Women's health, Chemotherapy, Editors, Health, Women's issues/gender studies
Abstract

2019 MAY 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Oncology - Ovarian Cancer. According to news reporting from [...]

Published
2019

27. Investigators at University of California School of Medicine Release New Data on Breast Cancer (Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib)

Subjects
Breast cancer -- Drug therapy, DNA damage, Physical fitness, Niraparib, Rucaparib, Olaparib, Obesity, Niacinamide, Proteins, DNA, Editors, Health
Abstract

2019 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Breast Cancer. According to news [...]

Published
2019

28. Researchers at Washington University Have Reported New Data on Ovarian Cancer (Novel Treatment Options In Platinum-sensitive Recurrent Ovarian Cancer: a Review)

Subjects
Cancer research, Niraparib, Ovarian cancer -- Drug therapy, Recurrence (Disease) -- Drug therapy, Rucaparib, Bevacizumab, Olaparib, Women's health, Death, Editors, Health, Women's issues/gender studies, Washington University
Abstract

2019 MAR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on Oncology - Ovarian Cancer is now available. According to news [...]

Published
2019

29. GSK acquires Massachusetts-based oncology focused biopharma company, Tesaro for $5.1 billion

Subjects
GlaxoSmithKline PLC -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Mergers, acquisitions and divestments, Ovarian cancer, Biological products industry -- Mergers, acquisitions and divestments, Niraparib, Monosaccharides, Company acquisition/merger, Pharmaceuticals and cosmetics industries, Zejula (Medication)
Abstract

GlaxoSmithKline plc announced that it has successfully completed the acquisition of Tesaro, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (4.0 [...]

Published
2019

30. GlaxoSmithKline (LSE: GSK)

Subjects
United States. Food and Drug Administration, Pfizer Inc. -- Joint ventures, GlaxoSmithKline PLC -- Joint ventures, Niraparib, Rilpivirine, Health care industry -- Joint ventures, Dolutegravir, Pembrolizumab, Pharmaceutical industry -- Joint ventures, Belimumab, Drugstores, Pharmacy, Health care industry, Company joint venture, Business, international, Seretide (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Tivicay (Medication), Nucala (Medication), Pediarix (Vaccine), Benlysta (Medication), Infanrix (Medication), Dovato (Medication), Advair Diskus (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

31. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

32. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline pic was formed in 2000 as a result of [...]

Published
2019

33. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

34. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

35. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

36. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

37. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

38. GlaxoSmithKline PLC to Discuss Data Presented at ESMO - Final

Subjects
GlaxoSmithKline PLC, Niraparib, Olaparib, Bevacizumab, Pharmaceutical industry, Media executives, Business, Zejula (Medication), Avastin (Medication)
Abstract

Presentation OPERATOR: A very good day, and welcome to the GSK ESMO Investor Call. (Operator Instructions) I would also like to advise all parties this conference is being recorded. And [...]

Published
2019

39. Zai Lab Ltd Corporate Analyst Meeting - Final

Subjects
Zai Lab Ltd., Pharmaceutical industry, Niraparib, Vice presidents (Organizations), Business, Herceptin (Medication), Optune (Medical instrument)
Abstract

Presentation JONATHAN J. WANG, SENIOR VP & HEAD OF BUSINESS DEVELOPMENT, ZAI LAB LIMITED: Hello and good afternoon. My name is Jonathan Wang, and I'm the Head of Business development [...]

Published
2019

41. Rammeaftale Om Kb Af Zejula (niraparib) 2020 - In1.603.a (denmark-copenhagen: Pharmaceutical Products)

Subjects
GlaxoSmithKline Pharma A/S -- Officials and employees, Niraparib, Pharmaceutical industry -- Officials and employees, Business, international, Zejula (Medication)
Abstract

Contract award notice: Rammeaftale om kb af zejula (niraparib) 2020 - in1.603.a (denmark-copenhagen: Pharmaceutical products) Formlet med rammeaftalen er at kunne forsyne sygehusapotekerne hos Amgros~ interessenter med lgemidlet Zejula (niraparib). [...]

Published
2020

42. European Commission Approves Niraparib as Maintenance Treatment in Advanced Ovarian Cancer

Subjects
United States. Food and Drug Administration, Niraparib, Chemotherapy, Ovarian cancer -- Drug therapy, Business, international, Law, European Union. European Commission
Abstract

The European Commission has approved niraparib (Zejula; GSK), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as first-line monotherapy maintenance treatment for adult patients with advanced epithelial (FIGO Stages III [...]

Published
2020

43. Onxeo Announces Enrollment of First Patient in Phase Ib|II Study Revocan

Subjects
Cancer treatment, Niraparib, Medical research, Ovarian cancer -- Care and treatment, General interest, News, opinion and commentary
Abstract

PARIS: Onxeo S.A. has issued the following news release: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ('Onxeo' or 'the Company'), a clinical-stage biotechnology company specializing in the development of innovative [...]

Published
2020

44. Onxeo Announces Enrollment of First Patient in Phase Ib|II Study Revocan

Subjects
Cancer treatment, DNA damage, Niraparib, Medical research, Carboplatin, Ovarian cancer -- Care and treatment -- Development and progression, Business, international, Law
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), [...]

Published
2020

45. Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

Subjects
Cancer treatment, DNA damage, Niraparib, Medical research, Carboplatin, Ovarian cancer -- Care and treatment -- Development and progression, Banking, finance and accounting industries, Business
Abstract

PARIS, Oct 21, 2020 (GLOBE NEWSWIRE via COMTEX) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ('Onxeo' or 'the Company'), a clinical-stage biotechnology company specializing in the development of innovative [...]

Published
2020

46. For women with ovarian cancer, early communication is key

Subjects
Niraparib, Women, Ovarian cancer, News, opinion and commentary, Sports and fitness, Zejula (Medication)
Abstract

- At first thought, it would appear that Cherie, age 50 from Chicago, Illinois, and Leanne, age 62 from White Plains, New York, don't have much in common. Cherie enjoys [...]

Published
2020

47. For women with ovarian cancer, early communication is key

Subjects
Niraparib, Women, Ovarian cancer, News, opinion and commentary, Sports and fitness, Zejula (Medication)
Abstract

- At first thought, it would appear that Cherie, age 50 from Chicago, Illinois, and Leanne, age 62 from White Plains, New York, don't have much in common. Cherie enjoys [...]

Published
2020

48. GSKs Zejula and AZs Lynparza leap toward broader EU approval

Subjects
Niraparib, Bevacizumab, Ovarian cancer, Business, international, Law, Zejula (Medication), Lynparza (Medication)
Abstract

GlaxoSmithKlines Zejula and AstraZenecas Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human [...]

Published
2020

49. Positive EU Committee Opinion For GlaxoSmithKline's Zejula

Subjects
GlaxoSmithKline PLC, Niraparib, Chemotherapy, Ovarian cancer, General interest, News, opinion and commentary, Zejula (Medication)
Abstract

London: GlaxoSmithKline PLC has issued the following press release: GlaxoSmithKline PLC on Friday reported that a European Medicines Agency committee has adopted a positive opinion on its cancer drug Zejula. [...]

Published
2020

50. 61|971|2020 Medicine Niraparib 100 Mg Capsule

Subjects
Niraparib, Business, international
Abstract

Contract awarded for 61/971/2020 medicine niraparib 100 mg capsule Date of conclusion of the contract: 21-02-2020 Contract price: 68. 625,50 Deadline: 314 days Place of execution - Country, District, Municipality: [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results